{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:20Z","timestamp":1791501740344,"version":"4.3.4"},"reference-count":154,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer remains a leading global health burden, profoundly affecting patient survival and quality of life. Current treatments\u2014including chemotherapy, radiotherapy, immunotherapy, and surgery\u2014are often limited by toxicity or insufficient specificity. Conventional chemotherapy, for instance, indiscriminately attacks rapidly dividing cells, causing severe side effects. In contrast, peptide-based therapeutics offer a paradigm shift, combining high tumour-targeting precision with minimal off-target effects. Their low immunogenicity, multi-pathway modulation capabilities, and adaptability for diagnostics and therapy make them ideal candidates for advancing oncology care. Innovative peptide platforms now enable three transformative applications: (1) precision molecular diagnostics (e.g., 18F-PSMA-1007 for prostate cancer detection), (2) targeted therapies (e.g., BT5528 and SAR408701 targeting tumour-specific antigens), and (3) theranostic systems (e.g., RAYZ-8009 and 177Lu-FAP-2286 integrating imaging and radiotherapy). Despite their promise, peptides face challenges like metabolic instability and short half-lives. Recent advances in structural engineering (e.g., cyclization and D-amino acid incorporation) and delivery systems (e.g., nanoparticles and PEGylation) have significantly enhanced their clinical potential. This review highlights peptide-based agents in development, showcasing their ability to improve early cancer detection, reduce metastasis, and enhance therapeutic efficacy with fewer adverse effects. Examples like CLP002 underscore their role in personalised medicine. By overcoming current limitations, peptide drugs are poised to redefine cancer management, offering safer, more effective alternatives to conventional therapies. Their integration into clinical practice could mark a critical milestone in achieving precision oncology.<\/jats:p>","DOI":"10.3390\/ijms26146815","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:48:22Z","timestamp":1752680902000},"page":"6815","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9815-1518","authenticated-orcid":false,"given":"Yanyamba","family":"Nsereko","sequence":"first","affiliation":[{"name":"School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4919-1223","authenticated-orcid":false,"given":"Amy","family":"Armstrong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5129-6110","authenticated-orcid":false,"given":"Fleur","family":"Coburn","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-1825","authenticated-orcid":false,"given":"Othman","family":"Al Musaimi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"},{"name":"Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK"},{"name":"Orthogonal Peptides Limited, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dickerson, H., Diab, A., and Al Musaimi, O. (2024). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810008"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2174\/1871520621666210811105344","article-title":"Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy","volume":"22","author":"Karati","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/med.20242","article-title":"Drugs that target dynamic microtubules: A new molecular perspective","volume":"31","author":"Stanton","year":"2011","journal-title":"Med. Res. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI126046","article-title":"Immunotherapy transforms cancer treatment","volume":"129","author":"Zaidi","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104206","DOI":"10.1016\/j.drudis.2024.104206","article-title":"Peptides as innovative strategies to combat drug resistance in cancer therapy","volume":"29","author":"Lamb","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_7","unstructured":"(2025, July 10). Lumisight Approval. Available online: https:\/\/lumicell.com\/the-science-propelling-lumicell\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"967347","DOI":"10.1155\/2012\/967347","article-title":"Cancer treatment using peptides: Current therapies and future prospects","volume":"2012","author":"Thundimadathil","year":"2012","journal-title":"J. Amino Acids"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O. (2024). Peptide Therapeutics: Unveiling the Potential against Cancer\u2014A Journey through 1989. Cancers, 16.","DOI":"10.3390\/cancers16051032"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","volume":"93","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri.2016.29","article-title":"The immunology of host defence peptides: Beyond antimicrobial activity","volume":"16","author":"Hancock","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jensen, S.M., Potts, G.K., Ready, D.B., and Patterson, M.J. (2018). Specific MHC-I Peptides Are Induced Using PROTACs. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02697"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"de la Torre, B.G., and Albericio, F. (2025). The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules. Molecules, 30.","DOI":"10.20944\/preprints202501.0253.v1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.drudis.2022.103464","article-title":"Peptide-based drug discovery: Current status and recent advances","volume":"28","author":"Sharma","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_17","first-page":"e3627","article-title":"FDA\u2019s stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond","volume":"30","year":"2024","journal-title":"J. Pept. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70040","DOI":"10.1002\/psc.70040","article-title":"Peptide\u2013Drug Conjugates: A New Hope for Cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, D., Yin, F., Li, Z., Zhang, Y., and Shi, C. (2025). Current progress and remaining challenges of peptide\u2013drug conjugates (PDCs): Next generation of antibody-drug conjugates (ADCs)?. J. Nanobiotechnol., 23.","DOI":"10.1186\/s12951-025-03277-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116119","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: A new paradigm for targeted cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide-drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics"},{"key":"ref_24","unstructured":"(2025, July 10). 68Ga-NTA-476 Imaging in Prostate Cancer. Available online: https:\/\/clin.larvol.com\/trial-detail\/ACTRN12623001157662."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"TPS295","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS295","article-title":"Phase 1\/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_26","unstructured":"(2025, July 10). First Human Trial of Targeting MDM2\/MDMX PET Imaging. Available online: https:\/\/clin.larvol.com\/trial-detail\/NCT06443762."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2022.40.16_suppl.3069","article-title":"The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study","volume":"40","author":"Kenny","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, J., Li, Y., Lian, X., Zhang, C., Feng, J., Tao, H., and Wang, Z. (2025). Potential target within the tumor microenvironment\u2014MT1-MMP. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1517519"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-19-4156","article-title":"First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma","volume":"26","author":"Deken","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s11307-018-1178-y","article-title":"Comparison of [(99m)Tc]3PRGD(2) Imaging and [(18)F]FDG PET\/CT in Breast Cancer and Expression of Integrin \u03b1(v)\u03b2(3) in Breast Cancer Vascular Endothelial Cells","volume":"20","author":"Chen","year":"2018","journal-title":"Mol. Imaging. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/IGC.0000000000000044","article-title":"Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: A multicenter phase 2 trial (AGO-GYN5)","volume":"24","author":"Emons","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","article-title":"MMAE Delivery Using the Bicycle Toxin Conjugate BT5528","volume":"19","author":"Bennett","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1016\/j.annonc.2020.08.713","article-title":"599TiP BT8009-100 phase I\/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies","volume":"31","author":"McKean","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.annonc.2024.08.735","article-title":"669P CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors","volume":"35","author":"Lorusso","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2021.39.15_suppl.3077","article-title":"Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate targeting FR\u03b1 and TRPV6, in patients with advanced solid tumors","volume":"39","author":"Gong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-020-01015-9","article-title":"Targeting oncogenic Notch signaling with SERCA inhibitors","volume":"14","author":"Pagliaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Solanki, H.K., Davidson, M., Apostolopoulos, V., and Bojarska, J. (2022). Peptide-Drug Conjugates: A New Hope for Cancer Management. Molecules, 27.","DOI":"10.3390\/molecules27217232"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide-drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Demeule, M., Charfi, C., Currie, J.C., Zgheib, A., Danalache, B.A., B\u00e9liveau, R., Marsolais, C., and Annabi, B. (2022). The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091910"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Charfi, C., Demeule, M., Currie, J.C., Larocque, A., Zgheib, A., Danalache, B.A., Ouanouki, A., B\u00e9liveau, R., Marsolais, C., and Annabi, B. (2021). New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.760787"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e011422","DOI":"10.1136\/jitc-2024-011422","article-title":"Conformation-sensitive targeting of CD18 depletes M2-like tumor-associated macrophages resulting in inhibition of solid tumor progression","volume":"13","author":"Han","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.actbio.2024.12.051","article-title":"Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy","volume":"193","author":"Zhao","year":"2025","journal-title":"Acta Biomater."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"16610","DOI":"10.1021\/jacs.3c03886","article-title":"Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor","volume":"145","author":"Tanada","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_48","first-page":"A228","article-title":"374 A first-in-human Phase 1\/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors","volume":"8","author":"Mahalingam","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","article-title":"Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized \u03b1-Helical Peptide in Clinical Development","volume":"66","author":"Guerlavais","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity","volume":"11","author":"Zhou","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_51","first-page":"Abstract nr CT017","article-title":"A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR","volume":"79","author":"Wei","year":"2019","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hackenbruch, C., Bauer, J., Heitmann, J.S., Maringer, Y., Nelde, A., Denk, M., Zieschang, L., Kammer, C., Federmann, B., and Jung, S. (2024). FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1367450"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e011108","DOI":"10.1136\/jitc-2024-011108","article-title":"METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5\/CCL5 regulation","volume":"13","author":"Tong","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","unstructured":"Ohio State University Comprehensive Cancer Center (2025, July 10). BZLF1 Peptide Vaccine (OSU-2131) with QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants. Available online: https:\/\/clin.larvol.com\/trial-detail\/NCT06741072."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e70020","DOI":"10.1002\/ctm2.70020","article-title":"NY-ESO-1 antigen: A promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-22-3168","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma","volume":"29","author":"Schoen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_57","unstructured":"(2025, July 10). ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium. Available online: https:\/\/www.biospace.com\/press-releases\/proteinqure-to-present-data-on-pq203-a-novel-peptide-drug-conjugate-for-triple-negative-breast-cancer-at-2024-san-antonio-breast-cancer-symposium."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"vdae186","DOI":"10.1093\/noajnl\/vdae186","article-title":"Phase II trial of blood\u2013brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma","volume":"6","author":"Dmello","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10637-017-0438-z","article-title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","volume":"35","author":"Fu","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_61","unstructured":"Memorial Sloan Kettering Cancer Center (2025, July 10). Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients with Advanced, Well-Differentiated Neuroendocrine Tumors. Available online: https:\/\/www.mskcc.org\/cancer-care\/clinical-trials\/21-362."},{"key":"ref_62","unstructured":"Novartis (2025, July 10). A Study of 177Lu-FAP-2286 in Advanced Solid Tumors. Available online: https:\/\/www.novartis.com\/clinicaltrials\/study\/nct04939610."},{"key":"ref_63","unstructured":"(2025, July 10). Zoptarelin Doxorubicin Fails to Improve Survival in Phase III Endometrial Cancer Trial. Available online: https:\/\/www.targetedonc.com\/view\/zoptarelin-doxorubicin-fails-to-improve-survival-in-phase-iii-endometrial-cancer-trial."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O., AlShaer, D., de la Torre, B.G., and Albericio, F. (2025). 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030291"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Harris, P.E., and Zhernosekov, K. (2022). The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.941832"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.2174\/1568026620666200226104652","article-title":"Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward","volume":"20","author":"Feijtel","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e220157","DOI":"10.1148\/rycan.220157","article-title":"A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cheng, X., Li, C., Hong, H., Zhou, Z., and Wu, Z. (2025). Macrocyclic RGD-Peptides with High Selectivity for \u03b1v\u03b23 Integrin in Cancer Imaging and Therapy. RSC Med. Chem.","DOI":"10.1039\/D5MD00280J"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1021\/mp200039s","article-title":"Novel Tetrapeptide, RGDF, Mediated Tumor Specific Liposomal Doxorubicin (DOX) Preparations","volume":"8","author":"Du","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171317","DOI":"10.1016\/j.peptides.2024.171317","article-title":"Lasso Peptides Realm: Insights and Applications","volume":"182","year":"2024","journal-title":"Peptides"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Heh, E., Allen, J., Ramirez, F., Lovasz, D., Fernandez, L., Hogg, T., Riva, H., Holland, N., and Chacon, J. (2023). Peptide Drug Conjugates and Their Role in Cancer Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010829"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Nh\u00e0n, N.T.T., Yamada, T., and Yamada, K.H. (2023). Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612931"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1021\/acschembio.2c00276","article-title":"Characterization of the Key Determinants of Phd Antitoxin Mediated Doc Toxin Inactivation in Salmonella","volume":"17","author":"Worm","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1039\/D1SC00165E","article-title":"Peptide-based inhibitors of protein-protein interactions: Biophysical, structural and cellular consequences of introducing a constraint","volume":"12","author":"Wang","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","article-title":"Gonadotropin-releasing-hormone-receptor antagonists","volume":"358","author":"Hurine","year":"2001","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1210\/endo.141.2.7300","article-title":"Primary structure and function of three gonadotropin-releasing hormones, including a novel form, from an ancient teleost, herring","volume":"141","author":"Carolsfeld","year":"2000","journal-title":"Endocrinology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1039\/C4MD00486H","article-title":"Radiosynthesis of high affinity fluorine-18 labeled GnRH peptide analogues: In vitro studies and in vivo assessment of brain uptake in rats","volume":"6","author":"Olberg","year":"2015","journal-title":"MedChemComm"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gr\u00fcndker, C., and Emons, G. (2017). The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00187"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hawry\u0142kiewicz, A., and Ptaszy\u0144ska, N. (2021). Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy. Molecules, 26.","DOI":"10.3390\/molecules26020364"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/er.2003-0039","article-title":"Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans","volume":"26","author":"Cheng","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.yfrne.2003.10.003","article-title":"The biology of gonadotropin hormone-releasing hormone: Role in the control of tumor growth and progression in humans","volume":"24","author":"Limonta","year":"2003","journal-title":"Front. Neuroendocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.nucmedbio.2016.05.003","article-title":"Brain penetrant small molecule (18)F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats","volume":"43","author":"Olberg","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_84","first-page":"Cd001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Youssef","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Markatos, C., Biniari, G., Chepurny, O.G., Karageorgos, V., Tsakalakis, N., Komontachakis, G., Vlata, Z., Venihaki, M., Holz, G.G., and Tselios, T. (2024). Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells. Molecules, 29.","DOI":"10.3390\/molecules29174127"},{"key":"ref_86","unstructured":"(2025, July 10). Degarelix Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022201s000_Lbl.pdf."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acs.oprd.9b00430","article-title":"Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix","volume":"23","author":"Guryanov","year":"2019","journal-title":"Part 1. Org. Process Res. Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14740338.2022.1989409","article-title":"Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids","volume":"21","author":"Ali","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41422-022-00679-x","article-title":"Structural insights into ligand recognition and selectivity of somatostatin receptors","volume":"32","author":"Zhao","year":"2022","journal-title":"Cell Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: From signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF03350317","article-title":"Molecular pharmacology of somatostatin receptor subtypes","volume":"20","author":"Patel","year":"1997","journal-title":"J. Endocrinol. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bpg.2013.01.004","article-title":"Peptide receptor radionuclide therapy (PRRT) for GEP-NETs","volume":"26","author":"Bergsma","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_93","unstructured":"(2025, July 10). Octreotide Approval Letter and Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/021008a_appltr_prntlbl.pdf."},{"key":"ref_94","unstructured":"(2025, July 10). Mycapssa Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/208232Orig1s000AdminCorres.pdf."},{"key":"ref_95","unstructured":"Ray, S.D. (2017). Chapter 38\u2014Miscellaneous Hormones. Side Effects of Drugs Annual, Elsevier."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ladri\u00e8re, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., and Vigne, J. (2023). Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041240"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Stueven, A.K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B., Roderburg, C., and Jann, H. (2019). Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123049"},{"key":"ref_98","unstructured":"(2025, July 10). Lanreotide Approval Letter. 2007. Chrome-Extension, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022074s000_Approv.pdf."},{"key":"ref_99","unstructured":"(2025, July 10). Lanreotide Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215395s000lbl.pdf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Juliana, C.A., Chai, J., Arroyo, P., Rico-Bautista, E., Betz, S.F., and De Le\u00f3n, D.D. (2023). A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.104816"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Rogoza, O., Megnis, K., Kudrjavceva, M., Gerina-Berzina, A., and Rovite, V. (2022). Role of Somatostatin Signalling in Neuroendocrine Tumours. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031447"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gourni, E., and Henriksen, G. (2017). Metal-Based PSMA Radioligands. Molecules, 22.","DOI":"10.3390\/molecules22040523"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J. Cell Biochem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1158\/0008-5472.CAN-06-1520","article-title":"A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity","volume":"66","author":"Aggarwal","year":"2006","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jmb.2007.12.066","article-title":"Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs","volume":"376","author":"Barinka","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1107\/S174430910700379X","article-title":"A high-resolution structure of ligand-free human glutamate carboxypeptidase II","volume":"63","author":"Barinka","year":"2007","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_111","unstructured":"(2025, July 10). Pluvicto Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.crad.2020.06.031","article-title":"Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: Normal patterns, pearls, and pitfalls","volume":"75","author":"Foley","year":"2020","journal-title":"Clin. Radiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III Study of (18)F-PSMA-1007 Versus (18)F-Fluorocholine PET\/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study","volume":"64","author":"Olivier","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors","volume":"50","author":"Basu","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rosar, F., Kochems, N., Bartholom\u00e4, M., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., and Ezziddin, S. (2021). Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers, 13.","DOI":"10.3390\/cancers13123095"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_117","unstructured":"(2021, January 16). Detectnet Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213227s000lbl.pdf."},{"key":"ref_118","unstructured":"(2025, July 10). PeptiDream Announces Initial Public Offering of RayzeBio and Update on GPC3 Program. Available online: https:\/\/uk.marketscreener.com\/quote\/stock\/PEPTIDREAM-INC-13370541\/news\/PeptiDream-Announces-Initial-Public-Offering-of-RayzeBio-and-Update-on-GPC3-Program-44886778\/."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"de la Torre, B.G., and Albericio, F. (2023). The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 28.","DOI":"10.3390\/molecules28031038"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-12-394308-8.00003-0","article-title":"Fibroblast activation protein-\u03b1: A key modulator of the microenvironment in multiple pathologies","volume":"297","author":"Kelly","year":"2012","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_121","unstructured":"(2025, July 10). A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) Study Details Tab Study Overview, Available online: https:\/\/clinicaltrials.gov\/about-site\/disclaimer."},{"key":"ref_122","first-page":"2271","article-title":"177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1\/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)","volume":"63","author":"McConathy","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_124","unstructured":"(2025, July 10). Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress. Available online: https:\/\/www.businesswire.com\/news\/home\/20221017005267\/en\/Clovis-Oncology-Highlights-Updated-LuMIERE-Phase-1-Data-of-Targeted-Radiotherapy-Candidate-FAP-2286-at-the-35th-Annual-EANM-Congress."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Shirpour, A., Hadadi, A., Zolghadri, S., Vosoughi, S., and Rajabifar, S. (2025). Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91716-3"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates--an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","article-title":"Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates","volume":"28","author":"Cazzamalli","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_130","unstructured":"(2025, July 10). TIVDAK Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761208Orig1s000lbledt.pdf."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100952","DOI":"10.1016\/j.currproblcancer.2023.100952","article-title":"Tisotumab vedotin in recurrent or metastatic cervical cancer","volume":"47","author":"Bogani","year":"2023","journal-title":"Curr. Probl. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"Concin","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1538-7445.AM2019-221","article-title":"Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro","volume":"79","author":"Alley","year":"2019","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates","volume":"14","author":"Satijn","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","first-page":"e1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"Harris","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fan, S., Zhong, W., Zhou, X., and Li, S. (2017). Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091860"},{"key":"ref_137","unstructured":"(2025, July 10). CEACAM5-Directed Tusamitamab Ravtansine Progresses to Phase 3 Trial in NSCLC. Available online: https:\/\/www.onclive.com\/view\/ceacam5-directed-tusamitamab-ravtansine-progresses-to-phase-3-trial-in-nsclc."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hoppenz, P., Els-Heindl, S., and Beck-Sickinger, A.G. (2020). Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front. Chem., 8.","DOI":"10.3389\/fchem.2020.00571"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera\u00ae: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101374","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_141","unstructured":"(2025, July 10). Pepaxti Drug Approval Letter. Available online: https:\/\/www.pharmaceutical-technology.com\/news\/mhra-oncopeptides-multiple-myeloma-drug\/#:~:text=MHRA%20grants%20marketing%20authorisation%20for,or%20following%20the%20last%20treatment."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.23.01107","article-title":"Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors","volume":"42","author":"Bashir","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O., Lombardi, L., Williams, D.R., and Albericio, F. (2022). Strategies for Improving Peptide Stability and Delivery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101283"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/tcr.201600005","article-title":"D-Peptides as Recognition Molecules and Therapeutic Agents","volume":"16","author":"Liu","year":"2016","journal-title":"Chem. Rec."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.1128\/JVI.01339-10","article-title":"Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance","volume":"84","author":"Welch","year":"2010","journal-title":"J. Virol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/anie.201000329","article-title":"A left-handed solution to peptide inhibition of the p53-MDM2 interaction","volume":"49","author":"Liu","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Maxian, T., Gerlitz, L., Riedl, S., Rinner, B., and Zweytick, D. (2021). Effect of L- to D-Amino Acid Substitution on Stability and Activity of Antitumor Peptide RDP215 against Human Melanoma and Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168469"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/cbmi.4c00071","article-title":"Determining the Multivalent Effects of d-Peptide-Based Radiotracers","volume":"3","author":"Zhang","year":"2025","journal-title":"Chem. Biomed. Imaging"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2002197","DOI":"10.1002\/adhm.202002197","article-title":"An NRP1\/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy","volume":"10","author":"Zhou","year":"2021","journal-title":"Adv. Healthc. Mater."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6815\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:56Z","timestamp":1760033456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":154,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146815"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146815","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}